Patent ID: 11896657
Assignee: GEOVAX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A recombinant modified vaccinia ankara (MVA) vector comprising:
i) a first nucleic acid encoding a Marburg virus (MARV) glycoprotein, and
ii) a second nucleic acid sequence encoding a Marburg virus (MARV) VP40 matrix protein;
wherein both the first nucleic acid sequence and the second nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems;
wherein the first nucleic acid is located between MVA genes I8R and G1L;
wherein the second nucleic acid sequence is located between MVA genes A50R and B1R in a restructured and modified deletion site III; and
wherein the MARV glycoprotein and the MARV VP40 matrix protein are capable of assembling into virus-like particles (VLPs) when expressed in a host cell.